Sarepta Closes Enrollment in Elevidys Phase 3 Trial, Leaving Non-Ambulatory Duchenne Patients Dependent on a 25-Person Safety Study

Sarepta halts enrollment in confirmatory Phase 3 trial of Elevidys

Sarepta Therapeutics announced it will not enroll additional patients in the confirmatory Phase 3 trial of Elevidys, its Duchenne muscular dystrophy gene therapy, a study required to maintain the drug's accelerated approval.